Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

81 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting prostaglandin E EP receptors to inhibit metastasis.
Fulton AM, Ma X, Kundu N. Fulton AM, et al. Cancer Res. 2006 Oct 15;66(20):9794-7. doi: 10.1158/0008-5472.CAN-06-2067. Cancer Res. 2006. PMID: 17047037 Review.
CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model.
Ma X, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D, Fulton A. Ma X, et al. Among authors: fulton a. Mol Cancer Ther. 2009 Mar;8(3):490-8. doi: 10.1158/1535-7163.MCT-08-0485. Epub 2009 Mar 10. Mol Cancer Ther. 2009. PMID: 19276169
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties.
Kundu N, Ma X, Kochel T, Goloubeva O, Staats P, Thompson K, Martin S, Reader J, Take Y, Collin P, Fulton A. Kundu N, et al. Among authors: fulton a. Breast Cancer Res Treat. 2014 Jan;143(1):19-31. doi: 10.1007/s10549-013-2779-4. Epub 2013 Nov 27. Breast Cancer Res Treat. 2014. PMID: 24281828 Free PMC article.
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.
Reader J, Holt D, Fulton A. Reader J, et al. Among authors: fulton a. Cancer Metastasis Rev. 2011 Dec;30(3-4):449-63. doi: 10.1007/s10555-011-9303-2. Cancer Metastasis Rev. 2011. PMID: 22002714 Free PMC article. Review.
Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4.
Holt D, Ma X, Kundu N, Fulton A. Holt D, et al. Among authors: fulton a. Cancer Immunol Immunother. 2011 Nov;60(11):1577-86. doi: 10.1007/s00262-011-1064-9. Epub 2011 Jun 17. Cancer Immunol Immunother. 2011. PMID: 21681369 Free PMC article.
An unsupervised approach to identify molecular phenotypic components influencing breast cancer features.
Selaru FM, Yin J, Olaru A, Mori Y, Xu Y, Epstein SH, Sato F, Deacu E, Wang S, Sterian A, Fulton A, Abraham JM, Shibata D, Baquet C, Stass SA, Meltzer SJ. Selaru FM, et al. Among authors: fulton a. Cancer Res. 2004 Mar 1;64(5):1584-8. doi: 10.1158/0008-5472.can-03-3208. Cancer Res. 2004. PMID: 14996713
Prospects of controlling breast cancer metastasis by immune intervention.
Fulton A, Miller F, Weise A, Wei WZ. Fulton A, et al. Breast Dis. 2006-2007;26:115-27. doi: 10.3233/bd-2007-26110. Breast Dis. 2006. PMID: 17473370 Review.
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis.
Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, Fulton AM. Ma X, et al. Among authors: fulton am. Oncoimmunology. 2013 Jan 1;2(1):e22647. doi: 10.4161/onci.22647. Oncoimmunology. 2013. PMID: 23482441 Free PMC article.
Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4.
Holt DM, Ma X, Kundu N, Collin PD, Fulton AM. Holt DM, et al. Among authors: fulton am. J Immunother. 2012 Feb-Mar;35(2):179-88. doi: 10.1097/CJI.0b013e318247a5e9. J Immunother. 2012. PMID: 22306906 Free PMC article.
81 results
Jump to page
Feedback